COMP <GO>
PAHC vs ABBV // EV/EBITDA & P/E VALUATION
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PAHC 5
— ABBV 8
▲ EV/EBITDA & P/E VALUATION LEADER: PAHC
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | 70.20% | -39.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 29.00% | -19.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.2x | 33.3x | -14.10 | PAHC | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 3.47% | +1.61 | PAHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | 24.60% | -16.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 6.90% | -3.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 8.60% | +18.80 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 2.27% | -1.04 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 5.33 | -2.46 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 65.1 | -8.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 113.1x | -85.60 | PAHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $513.86B | -$512.28B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | ABBV REV | PAHC GROSS % | ABBV GROSS % | PAHC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $61.16B | 30.9% | 70.2% | $80.1M | $17.82B |
| FY 2024 | $1.02B | $56.33B | 30.8% | 70.0% | $87.6M | $17.83B |
| FY 2023 | $977.9M | $54.32B | — | — | $13.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
ABBV // BETA 1.15